Hyperglycemia associated with the use of atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 23, 2001, Pages 30-38

  Lindenmayer, J P ^a   Nathan, A M ^a   Smith, R C ^a  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR;

DISEASE ASSOCIATION; DOSE RESPONSE; ETHNOLOGY; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PIRENZEPINE; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; UNITED STATES;

EID: 0034790949     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. National Standards for Diabetes Self-Management and American Diabetes Association Review Criteria
2. Current estimates from the National Health Interview Survey, 1995
3. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994
4. Knowledge, attitudes and behaviors related to physical activity among Native Americans with diabetes
5. Prevalence of diabetes and factors associated with diabetic complications in Oneida Indians
6. The blood sugar curve in mental disease
7. Phenothiazines and diabetes in hospitalized women
8. Delayed action of insulin in schizophrenia
9. Phenothiazines and diabetes in hospitalized women
10. A survey for unknown diabetics in a mental hospital: Men under age fifty
11. Diabetes mellitus and mental illness
12. Prevalence and correlates of diabetes in national schizophrenia samples
13. Characteristics of diabetes mellitus in schizophrenic patients
14. Diabetes mellitus in schizophrenic patients
15. Diabetic ketoacidosis and clozapine
16. Diabetic ketoacidosis associated with clozapine treatment
17. Diabetes mellitus induced by atypical antipsychotics
18. Severe hyperglycemia associated with high doses of clozapine
19. Ketoacidosis as a side-effect of clozapine: A case report
20. Diabetic ketoacidosis associated with clozapine treatment
21. Diabetic ketoacidosis with clozapine treatment
22. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
23. Schizophrenia and diabetes mellitus
24. Diabetic ketoacidosis from clozapine and lithium cotreatment
25. Clozapine monotherapy and ketoacidosis
26. Clozapine and associated diabetes mellitus
27. Clozapine-induced diabetic ketoacidosis
28. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment
29. New-onset diabetes and ketoacidosis with atypical antipsychotics
30. Novel antipsychotics and new onset diabetes
31. The effect of clozapine on glucose metabolism
32. Olanzapine-induced glucose dysregulation
33. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine and risperidone treated inpatients
34. Hyperglycemia associated with olanzapine
35. Diabetic ketoacidosis with olanzapine treatment
36. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
37. Hyperglycemia and ketoacidosis associated with olanzapine
38. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
39. Hyperglycemia and olanzapine
40. New-onset diabetes mellitus associated with quetiapine
41. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
42. Diabetic ketoacidosis associated with risperidone treatment?
43. Risperidone treatment for a patient suffering from schizophrenia and IDDM
44. A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the US
45. Association of newly reported diabetes and antipsychotics in psychosis patients: Findings from a large health plan database
46. Atypical antipsychotics and hyperglycaemia
47. Diabetes and schizophrenia: A preliminary study
48. Diabetes in chronic schizophrenia
49. Hyperglycemia in schizophrenic patients treated with olanzapine
50. Hyperglycemia in schizophrenic patients treated with olanzapine and clozapine
51. Abnormalities in glucose regulation during antipsychotic treatment in schizophrenia
52. Biochemical disturbances in mental disorders
53. Pathophysiological mechanism of the blood sugar discorrelations in insulin treatment of schizophrenia
54. Insulin resistance in olanzapine- and ziprasidone-treated patients: Interim results of a double-blind controlled 6-week trial
55. An overview of pathophysiology and treatment of insulin resistance
56. Atypical antipsychotic agents and diabetes mellitus
57. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome
58. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro
59. Regulation of circulating leptin in humans
60. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus
61. 2c serotonin receptors
62. Hyperglycemic properties of serotonin receptor antagonists
63. Antipsychotic-induced weight gain: A comprehensive research synthesis
64. Atypical antipsychotics